Atea Pharmaceuticals (AVIR) Capital Expenditures (2020 - 2022)
Atea Pharmaceuticals (AVIR) recorded quarterly Capital Expenditures of $20000.0 in Q3 2022, down 98.36% quarter-over-quarter from $1.2 million in Q2 2022.
Atea Pharmaceuticals (AVIR) Capital Expenditures (2020 - 2022) Analysis & Trends
Atea Pharmaceuticals' Capital Expenditures history runs 2 years deep, the most recent figure standing at $20000.0 for Q3 2022.
- In Q3 2022, Capital Expenditures changed N/A year-over-year to $20000.0; the TTM figure through Dec 2022 stood at $1.9 million (changed N/A YoY), while the FY2022 annual figure was $1.9 million, up 48475.0% from the prior year.
- Capital Expenditures was $20000.0 for Q3 2022 at Atea Pharmaceuticals, down from $1.2 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.2 million in Q2 2022 to a low of $5000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -63,220.27 |
| 10 | Atea Pharmaceuticals | 347.28 Mn | 347.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 20,000.00 |
| Sep 30, 2022 | 20,000.00 |
| Jun 30, 2022 | 1.22 Mn |
| Jun 30, 2022 | 1.22 Mn |
| Mar 31, 2022 | 702,000.00 |
| Mar 31, 2022 | 702,000.00 |
| Dec 31, 2020 | 5,000.00 |
| Dec 31, 2020 | 5,000.00 |
| Sep 30, 2020 | 15,000.00 |
| Sep 30, 2020 | 15,000.00 |